Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 6/20 | 0.80 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ATP4A | P20648 | 3/20 | 0.33 |
| ▸ | ATP4B | P51164 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532795 | 1.00 | ERBB2 (0.80) | ERBB2MINK1POLBATP4AATP4B | |
| SCHEMBL3668068 | 0.93 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BCYP19A1 | |
| SCHEMBL3668064 | 0.93 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BCYP19A1 | |
| SCHEMBL22397926 | 0.92 | ERBB2 (0.81) | ERBB2MINK1ATP4AATP4BFFAR1 | |
| SCHEMBL28480663 | 0.92 | ERBB2 (0.81) | ERBB2MINK1ATP4AATP4BFFAR1 | |
| SCHEMBL22398091 | 0.91 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BFFAR1 | |
| SCHEMBL22398052 | 0.91 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BCYP19A1 | |
| SCHEMBL22397904 | 0.91 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BCYP19A1 | |
| SCHEMBL22398093 | 0.91 | ERBB2 (0.80) | ERBB2MINK1ATP4AATP4BFFAR1 | |
| SCHEMBL6580527 | 0.91 | ERBB2 (0.83) | ERBB2MINK1ATP4AATP4BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205325-B2 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | claimed |
| JP-2006515019-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1613623-A1 | NOVEL OXAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-11 | — | — | EP | claimed |
| US-20040209933-A1 | Oxazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | US | claimed |
| WO-2004085434-A1 | NOVEL OXAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | claimed |
| CN-111886234-B | Heterocyclic mitochondrial activity inhibitors and uses thereof | 蒙特利尔大学 | 2023-12-15 | — | — | CN | disclosed |
| CN-111886234-A | Heterocyclic mitochondrial activity inhibitors and uses thereof | 蒙特利尔大学 | 2020-11-03 | — | — | CN | disclosed |
| EP-3704111-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | Université de Montréal (CA) | 2020-09-09 | — | — | EP | disclosed |
| US-7205325-B2 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1613623-A1 | NOVEL OXAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| US-20040209933-A1 | Oxazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | US | disclosed |
| WO-2004085434-A1 | NOVEL OXAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209933-A1 | Oxazole derivatives | OXA1L, SULT1E1, CYP3A7 | ERBB2 1048/4885MINK1 1545/4885POLB 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.